[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:c3-glomerulopathy":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":34,"states":35},"C3 glomerulopathy",4,[7,15,21,28],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04817618","Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.",[11],"Phase 3","RECRUITING","2026-08-26T02:16:22.235886Z","2026-05-05T02:43:28.850770Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT03955445","Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN",[11],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:27.393743Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT06989359","Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease",[25],"Phase 2","2026-08-26T02:15:40.343619Z","2026-05-05T02:35:31.644706Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT07029542","Home Reported Outcomes in C3G Study",[],"2026-08-26T02:18:26.932189Z","2026-05-13T02:55:06.607220Z",[],[36,40],{"state":37,"count":38,"slug":39},"Iowa",3,"iowa",{"state":41,"count":38,"slug":42},"New York","new-york"]